Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00892710 · ClinicalTrials.gov registry record · Phase 2
Trial of Poor Performance Status Patients (ToPPS)
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 172
- Enrollment target
- 20
- Study locations
NCT00892710 is a Phase 2 study of Non-Small Cell Lung Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 172 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT00892710, a Phase 2 study of Non-Small Cell Lung Cancer, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 172 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Pemetrexed
Study Locations (20)
Florida
- Aventura Medical Center - Aventura
- Collaborative Research Group/ Palm Beach Ins of Hem Onc - Boynton Beach
- Holy Cross Hospital - Fort Lauderdale
- Florida Cancer Specialists - Fort Myers
- Memorial Regional Cancer Center - Hollywood
- Watson Clinic Center for Cancer Care and Research - Lakeland
- Mount Sinai Comprehensive Cancer Center - Miami Beach
Arkansas
- Genesis Cancer Center - Hot Springs
- Northeast Arkansas Clinic - Jonesboro
Indiana
- Northern Indiana Cancer Research Consortium - South Bend
- RHHP/ Hope Cancer Center - Terra Haute
Ohio
- Oncology Hematology Care - Cincinnati
- Toledo Community Oncology Program - Toledo
Arizona
- Mayo Clinic - AZ - Scottsdale
California
- Wilshire Oncology Medical Group - LaVerne
Georgia
- Northeast Georgia Medical Center - Gainesville
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 172 participants |
| Start Date | 2009-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00892710
The ClinicalTrials.gov registry entry for NCT00892710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (74% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT00892710 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Arkansas, Indiana.
Frequently Asked Questions
What is clinical trial NCT00892710 about?
NCT00892710 is a clinical study titled "Trial of Poor Performance Status Patients (ToPPS)". The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
What is the current status of trial NCT00892710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2009-06. Estimated completion is 2015-05.
What conditions does trial NCT00892710 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT00892710?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT00892710?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00892710 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.